anti-biotin CAR T-cell therapy (Miltenyi Biotec/Eberhard Karls University Tuebingen)

N/A

Report date: 2025/03/14 16:21:28

Base Information

Drug Nameanti-biotin CAR T-cell therapy (Miltenyi Biotec/Eberhard Karls University Tuebingen)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionBiotin modulatorsT lymphocytes stimulantsImmunostimulants
TargetsUpdating
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryGermany
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMiltenyi GmbH
China Registration ClassN/A

Develop Information

Active CompaniesMiltenyi GmbHEberhard Karls University Tübingen
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A